These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11813462)

  • 1. Balsalazide disodium.
    Am J Health Syst Pharm; 2002 Jan; 59(1):27. PubMed ID: 11813462
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
    Hanauer SB
    Am J Gastroenterol; 2003 Mar; 98(3):697-8. PubMed ID: 12650813
    [No Abstract]   [Full Text] [Related]  

  • 3. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
    Farrell RJ; Peppercorn MA
    Am J Gastroenterol; 2002 Jun; 97(6):1283-5. PubMed ID: 12094839
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral balsalazide (Colazal) for ulcerative colitis.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):62-3. PubMed ID: 11468602
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
    Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
    Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review article: balsalazide therapy in ulcerative colitis.
    Ragunath K; Williams JG
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1549-54. PubMed ID: 11563993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
    Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
    Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
    Muijsers RB; Goa KL
    Drugs; 2002; 62(11):1689-705. PubMed ID: 12109930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mesalamine wars heat up-enter balsalazide.
    Cohen RD
    Gastroenterology; 2003 Feb; 124(2):574-5. PubMed ID: 12557164
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
    Johnson LK; Pruitt RE; Green JR
    Am J Gastroenterol; 2003 Jan; 98(1):216-9. PubMed ID: 12526969
    [No Abstract]   [Full Text] [Related]  

  • 11. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
    Green JR; Lobo AJ; Holdsworth CD; Leicester RJ; Gibson JA; Kerr GD; Hodgson HJ; Parkins KJ; Taylor MD
    Gastroenterology; 1998 Jan; 114(1):15-22. PubMed ID: 9428213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balsalazide.
    Prakash A; Spencer CM
    Drugs; 1998 Jul; 56(1):83-9; discussion 90. PubMed ID: 9664201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
    Mansfield JC; Giaffer MH; Cann PA; McKenna D; Thornton PC; Holdsworth CD
    Aliment Pharmacol Ther; 2002 Jan; 16(1):69-77. PubMed ID: 11856080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
    Green JR; Gibson JA; Kerr GD; Swarbrick ET; Lobo AJ; Holdsworth CD; Crowe JP; Schofield KJ; Taylor MD
    Aliment Pharmacol Ther; 1998 Dec; 12(12):1207-16. PubMed ID: 9882028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
    Green JR; Mansfield JC; Gibson JA; Kerr GD; Thornton PC
    Aliment Pharmacol Ther; 2002 Jan; 16(1):61-8. PubMed ID: 11856079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
    Lowry PW; Szumlanski CL; Weinshilboum RM; Sandborn WJ
    Gastroenterology; 1999 Jun; 116(6):1505-6. PubMed ID: 10391741
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of different mesalamine-releasing drugs.
    Gross V
    Gastroenterology; 1998 Nov; 115(5):1306-7. PubMed ID: 9797396
    [No Abstract]   [Full Text] [Related]  

  • 18. Will the real 5-aminosalicylic acid please stand up?
    Regueiro MD
    Inflamm Bowel Dis; 1999 May; 5(2):147-8. PubMed ID: 10338387
    [No Abstract]   [Full Text] [Related]  

  • 19. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
    Loftus EV; Kane SV; Bjorkman D
    Aliment Pharmacol Ther; 2004 Jan; 19(2):179-89. PubMed ID: 14723609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
    Kane SV; Bjorkman DJ
    Rev Gastroenterol Disord; 2003; 3(4):210-8. PubMed ID: 14668693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.